相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
Carrie J. Li et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Mats Jerkeman et al.
LANCET HAEMATOLOGY (2018)
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
Francesco Zaja et al.
HAEMATOLOGICA (2017)
COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY
C.S. Tam et al.
HEMATOLOGICAL ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
Michael Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
Francesco Zaja et al.
HAEMATOLOGICA (2017)
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M. Smith et al.
LANCET HAEMATOLOGY (2017)
The potential for chemotherapy-free strategies in mantle cell lymphoma
Peter Martin et al.
BLOOD (2017)
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity
Patrick R. Hagner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network
Eva Hoster et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trneny et al.
LANCET ONCOLOGY (2016)
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
T. E. Witzig et al.
ANNALS OF ONCOLOGY (2015)
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie-Helene Delfau-Larue et al.
BLOOD (2015)
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial
Andre Goy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Jia Ruan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
Xiaoxian Zhao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S. Kahl et al.
BLOOD (2014)
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study
Lena Nordstrom et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma
M. Axelrod et al.
LEUKEMIA (2014)
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
P. L. Zinzani et al.
ANNALS OF ONCOLOGY (2013)
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Andre Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
Carlo Visco et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
Madhav Desai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
Heather E. Eve et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects
Nianhang Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang et al.
LANCET ONCOLOGY (2012)
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
Ulrike Klein et al.
ANNALS OF HEMATOLOGY (2011)
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
T. E. Witzig et al.
ANNALS OF ONCOLOGY (2011)
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Perez-Galan et al.
BLOOD (2011)
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Jonathan W. Friedberg et al.
BLOOD (2011)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Christian H. Geisler et al.
BLOOD (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
Liang Zhang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Constantine S. Tam et al.
BLOOD (2009)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
Stephen M. Ansell et al.
CANCER (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Peter H. Wiernik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome
F Rubio-Moscardo et al.
BLOOD (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
K Dredge et al.
JOURNAL OF IMMUNOLOGY (2002)